Avalo Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Avalo Therapeutics

29/03/2023 14:31

* Avalo Therapeutics Inc  AVTX.OQ  reported a quarterly
adjusted
loss of $1.04​​ per share for the quarter ended in December. The
mean expectation of three analysts for the quarter was for a
loss of 73 cents per share.
    * Revenue rose 309.1% to $896.00 thousand from a year ago;
analysts expected $3.61 million. 
    * Avalo Therapeutics Inc's reported EPS for the quarter was
a loss
of $1.04​.
    * The mean earnings estimate of analysts had risen by
about 5.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Avalo Therapeutics Inc shares had fallen by 65.5% this
quarter.
    * The company reported a quarterly loss of $9.81 million.
    * Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $10.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 29 at 01:30 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.73          -1.04          Missed
 Sep. 30 2022      -1.09          0.34           Beat
 Jun. 30 2022      -1.77          -1.38          Beat
 Mar. 31 2022      -1.60          -2.40          Missed